316 related articles for article (PubMed ID: 24195603)
1. Biosafety challenges for use of lentiviral vectors in gene therapy.
Rothe M; Modlich U; Schambach A
Curr Gene Ther; 2013 Dec; 13(6):453-68. PubMed ID: 24195603
[TBL] [Abstract][Full Text] [Related]
2. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
Doi K; Takeuchi Y
Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
[TBL] [Abstract][Full Text] [Related]
3. Insertional gene activation by lentiviral and gammaretroviral vectors.
Bokhoven M; Stephen SL; Knight S; Gevers EF; Robinson IC; Takeuchi Y; Collins MK
J Virol; 2009 Jan; 83(1):283-94. PubMed ID: 18945765
[TBL] [Abstract][Full Text] [Related]
4. State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations.
Pauwels K; Gijsbers R; Toelen J; Schambach A; Willard-Gallo K; Verheust C; Debyser Z; Herman P
Curr Gene Ther; 2009 Dec; 9(6):459-74. PubMed ID: 20021330
[TBL] [Abstract][Full Text] [Related]
5. Biosafety considerations using gamma-retroviral vectors in gene therapy.
Deichmann A; Schmidt M
Curr Gene Ther; 2013 Dec; 13(6):469-77. PubMed ID: 24195605
[TBL] [Abstract][Full Text] [Related]
6. Trial watch: Clinical trial boost for lentiviral gene therapy.
Flight MH
Nat Rev Drug Discov; 2013 Sep; 12(9):654. PubMed ID: 23989781
[No Abstract] [Full Text] [Related]
7. Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing.
Knight S; Zhang F; Mueller-Kuller U; Bokhoven M; Gupta A; Broughton T; Sha S; Antoniou MN; Brendel C; Grez M; Thrasher AJ; Collins M; Takeuchi Y
J Virol; 2012 Sep; 86(17):9088-95. PubMed ID: 22696657
[TBL] [Abstract][Full Text] [Related]
8. Biosafety features of lentiviral vectors.
Schambach A; Zychlinski D; Ehrnstroem B; Baum C
Hum Gene Ther; 2013 Feb; 24(2):132-42. PubMed ID: 23311447
[TBL] [Abstract][Full Text] [Related]
9. Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications.
Kumar P; Woon-Khiong C
Curr Gene Ther; 2011 Apr; 11(2):144-53. PubMed ID: 21291355
[TBL] [Abstract][Full Text] [Related]
10. Gene delivery by lentivirus vectors.
Cockrell AS; Kafri T
Mol Biotechnol; 2007 Jul; 36(3):184-204. PubMed ID: 17873406
[TBL] [Abstract][Full Text] [Related]
11. Biosafety of lentiviral vectors.
Debyser Z
Curr Gene Ther; 2003 Dec; 3(6):517-25. PubMed ID: 14683448
[TBL] [Abstract][Full Text] [Related]
12. Biosafety of recombinant adeno-associated virus vectors.
Dismuke DJ; Tenenbaum L; Samulski RJ
Curr Gene Ther; 2013 Dec; 13(6):434-52. PubMed ID: 24195602
[TBL] [Abstract][Full Text] [Related]
13. Effect of the internal promoter on insertional gene activation by lentiviral vectors with an intact HIV long terminal repeat.
Knight S; Bokhoven M; Collins M; Takeuchi Y
J Virol; 2010 May; 84(9):4856-9. PubMed ID: 20181689
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy in Fanconi Anemia: A Matter of Time, Safety and Gene Transfer Tool Efficiency.
Verhoeyen E; Roman-Rodriguez FJ; Cosset FL; Levy C; Rio P
Curr Gene Ther; 2017; 16(5):297-308. PubMed ID: 28067165
[TBL] [Abstract][Full Text] [Related]
15. Ten years of gene therapy for primary immune deficiencies.
Aiuti A; Roncarolo MG
Hematology Am Soc Hematol Educ Program; 2009; ():682-9. PubMed ID: 20008254
[TBL] [Abstract][Full Text] [Related]
16. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo.
Cesana D; Ranzani M; Volpin M; Bartholomae C; Duros C; Artus A; Merella S; Benedicenti F; Sergi Sergi L; Sanvito F; Brombin C; Nonis A; Serio CD; Doglioni C; von Kalle C; Schmidt M; Cohen-Haguenauer O; Naldini L; Montini E
Mol Ther; 2014 Apr; 22(4):774-85. PubMed ID: 24441399
[TBL] [Abstract][Full Text] [Related]
17. Viral Vectors: The Road to Reducing Genotoxicity.
David RM; Doherty AT
Toxicol Sci; 2017 Feb; 155(2):315-325. PubMed ID: 27803388
[TBL] [Abstract][Full Text] [Related]
18. Novel bovine lentiviral vectors based on Jembrana disease virus.
Metharom P; Takyar S; Xia HH; Ellem KA; Macmillan J; Shepherd RW; Wilcox GE; Wei MQ
J Gene Med; 2000; 2(3):176-85. PubMed ID: 10894263
[TBL] [Abstract][Full Text] [Related]
19. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
20. Development of gene therapy for hematopoietic stem cells using lentiviral vectors.
Woods NB; Ooka A; Karlsson S
Leukemia; 2002 Apr; 16(4):563-9. PubMed ID: 11960333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
